MET and melanoma: For several malignancies such as non-small-cell lung cancer (NSCLC), breast, ovarian, and gastric cancers and melanoma, acquired resistance frequently involves activation of the HGF/Met pathway [1,2,3,4,5,6,7,8,9,53,54,55,56,57].